PP_1170x120_10-25-21

COVAXX

Aurobindo Pharma and COVAXX sign an exclusive agreement to develop and commercialize COVID-19 vaccine UB-612 for India and UNICEF

Aurobindo Pharma and COVAXX sign an exclusive agreement to develop and commercialize COVID-19 vaccine UB-612 for India and UNICEF

EAST WINDSOR, N.J.— Aurobindo Pharma Limited and COVAXX, a U.S.-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based Vaccine to fight COVID-19, for India and the United Nations Children’s Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.